Oncologists, hematologists elected to National Academy of Medicine

The National Academy of Medicine announced the election of 75 regular members and 10 international members.

Election to the academy — considered one of the highest honors in health and medicine — recognizes individuals who demonstrated outstanding professional achievement and commitment to service.

“This distinguished and diverse class of new members is a truly remarkable set of scholars and leaders whose impressive work has advanced science, improved health, and made the world a better place for everyone,” Victor J. Dzau, MD, president of National Academy of Medicine, said in a press release. “Their expertise in science, medicine, health and policy in the U.S. and around the globe will help our organization address today’s most pressing health challenges and inform the future of health and health care. It is my privilege to welcome these esteemed individuals to the National Academy of Medicine.”

The academy now has 2,178 members, including 159 international members.

Newly elected members who specialize in fields related to hematology and oncology include:

Andrea Califano, PhD, professor of chemical and systems biology in the departments of systems biology, biochemistry and molecular biophysics, and biomedical informatics at Institute of Cancer Genetics; director of JP Sulzberger Columbia Genome Center; and associate director of Herbert Irving Comprehensive Cancer Center at Columbia University;
Michael A. Caligiuri, MD, president and physician-in chief distinguished chair at City of Hope National Medical Center;
Elias Campo, MD, PhD, research director and professor of anatomic pathology at Hospital Clinic of Barcelona at University of Barcelona; as well as director of Institute of Biomedical Research August Pi i Sunyer in Barcelona.
Susan M. Domchek, MD, Basser professor in oncology at Abramson Cancer Center at University of Pennsylvania;
Benjamin Levine Ebert, MD, PhD, chair of medical oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School;
John Kuriyan, PhD, professor in the departments of molecular and cell biology and chemistry at University of California, Berkeley;
Linda M. Liau, MD, PhD, MBA, chair of the department of neurosurgery at David Geffen School of Medicine at University of California, Los Angeles;
Matthew Langer Meyerson, MD, PhD, professor of pathology at Harvard Medical School and Dana-Farber Cancer Institute;
Sean J. Morrison, PhD, professor and distinguished chair in pediatric research at Children’s Research Institute at University of Texas Southwestern Medical Center;
Kunle Odunsi, MD, PhD, FRCOG, FACOG, deputy director, chair of the department of gynecologic oncology and executive director of Center for Immunotherapy at Roswell Park Comprehensive Cancer Center;
Lori J. Pierce, MD, professor in the department of radiation oncology at University of Michigan School of Medicine, as well as vice provost for academic and faculty affairs at University of Michigan;
Judith A. Salerno, MD, MS, president of New York Academy of Medicine;
Arlene Sharpe, PhD, MD, co-chair and professor of comparative pathology in the department of microbiology and immunobiology at Harvard Medical School;
Marie Celeste Simon, PhD, scientific director and investigator at Abramson Family Cancer Research Institute, associate director of shared resources at Abramson Cancer Center at University of Pennsylvania;
Arthur H. Rubenstein, MBBCh, professor in the department of cell and developmental biology at Perelman School of Medicine at University of Pennsylvania;
Ronald John Weigel, MD, PhD, departmental executive officer and chair of the department of surgery at Carver College of Medicine at University of Iowa; and
Teresa Woodruff, PhD, professor and vice chair for research and chief of the division of reproductive science in the department of obstetrics and gynecology at Northwestern University.